Therapeutic modulation of Notch signalling — are we there yet?
- 30 April 2014
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Drug Discovery
- Vol. 13 (5), 357-378
- https://doi.org/10.1038/nrd4252
Abstract
The Notch signalling pathway is evolutionarily conserved and is crucial for the development and homeostasis of most tissues. Deregulated Notch signalling leads to various diseases, such as T cell leukaemia, Alagille syndrome and a stroke and dementia syndrome known as CADASIL, and so strategies to therapeutically modulate Notch signalling are of interest. Clinical trials of Notch pathway inhibitors in patients with solid tumours have been reported, and several approaches are under preclinical evaluation. In this Review, we focus on aspects of the pathway that are amenable to therapeutic intervention, diseases that could be targeted and the various Notch pathway modulation strategies that are currently being explored.Keywords
This publication has 293 references indexed in Scilit:
- A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumorsInvestigational New Drugs, 2013
- NOTCH1 mutations influence survival in chronic lymphocytic leukemia patientsBMC Cancer, 2013
- Fc‐fusion proteins: new developments and future perspectivesEMBO Molecular Medicine, 2012
- Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ‐secretase inhibitor targeting notch signalingPediatric Blood & Cancer, 2011
- Vertebrate Segmentation: From Cyclic Gene Networks to ScoliosisCell, 2011
- Molecular mechanisms of bile duct developmentThe International Journal of Biochemistry & Cell Biology, 2011
- Translocation of the Cytoplasmic Domain of ADAM13 to the Nucleus Is Essential for Calpain8-a Expression and Cranial Neural Crest Cell MigrationDevelopmental Cell, 2011
- Targeting Notch signaling pathway to overcome drug resistance for cancer therapyBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2010
- Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer DiseaseArchives of Neurology, 2008
- Rumi Is a CAP10 Domain Glycosyltransferase that Modifies Notch and Is Required for Notch SignalingCell, 2008